Title Image

SPONSORS

SPONSORS

For any inquiries regarding sponsorships, the exhibition or your custom-made promotional proposal please contact
Mr. George Lasithiotakis or Mr. Alexandros Terzis
by email at gla@era.gr or aterzis@era.gr.

AJL Ophthalmic, S.A. is the only Spanish company (July 1992) dedicated to the r&D, manufacture and marketing of medical devices in the field of Ophthalmology.

The company has reached a leading market postion thanks to the fulfillment of very exigent Regulatory and Quality Control Requirements, 3000 m2 facilities with cutting-edge tecnology as well as the most qualified personnel for the manufacture of its products.

AJL has an extensive sales network with presence in more than 80 countries.

Glaukos is an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal disease.

Mediphacos is a world-class company with over 50 years of experience in ophthalmology and presence in more than 60 countries in 5 continents. Our mission is to restore, preserve and improve human vision in collaboration with ophthalmologists through innovative, safe and effective products and services. Products featured: KERARING – intracorneal rings for corneal ectatic disorders, BIOS – trifocal IOLs, INTRALENS – posterior chamber phakic IOLs and more.

Regensight is introducing a revolutionary paradigm shift in keratoconus treatment based upon theranostics, which involves the integration of diagnostic and therapeutic capabilities within a single platform.
The integration of theranostics in C4V CHROMO4VIS device exploits simultaneous UV-A light mediated fluorescence imaging technique for assessing riboflavin concentration and enables targeted UV-A light photo-activation of the substance with predictive personalization of therapeutic outcome. The multicenter randomized ARGO clinical trial demonstrated that integrating theranostics in C4V CHROMO4VIS for treatment of keratoconus achieved 91% accuracy and 95% precision in predicting Kmax flattening at 1-year follow-up.
The C4V CHROMO4VIS device further incorporates AI and IoMT technologies that make the device more efficient with eye surgeons’ use.